ArticleLeukemia2026
Targeted degradation of CBP/p300 by CBPD-409 exhibits robust anti-myeloma activity.
S Corradini, M Maksimos, F Azab, S Arsalani, E Nwarunma, G Watt, R Soutar, M Powell, R Henderson, J Travers and 4 more
Abstract read
In one paragraphArticle in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
S Corradini *Research Centre for Health, School of Health and Life Sciences, Department of Biological and Biomedical Sciences, Glasgow Caledonian University, Glasgow, UK.ORCID http://orcid.org/0000-0002-5990-806X F AzabDepartment of Biomedical Engineering, University of Texas Southwestern, Dallas, TX, USA.
S ArsalaniDepartment of Biomedical Engineering, University of Texas Southwestern, Dallas, TX, USA.
G WattResearch Centre for Health, School of Health and Life Sciences, Department of Biological and Biomedical Sciences, Glasgow Caledonian University, Glasgow, UK.
R SoutarThe Beatson West of Scotland Cancer Centre, Glasgow, UK.
M PowellThe Beatson West of Scotland Cancer Centre, Glasgow, UK.
R HendersonThe Beatson West of Scotland Cancer Centre, Glasgow, UK.
J TraversThe Beatson West of Scotland Cancer Centre, Glasgow, UK.
Z ChenDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fujian, China.
S WangDepartment of Internal Medicine, Division of Hematology & Oncology, University of Michigan Medical School, Ann Arbor, MI, USA Rogel Cancer Center, The University of Michigan - Michigan Medicine, Ann Arbor, MI, USA Department of Pharmacology, Department of Medicinal Chemistry, University of Michigan Medical School, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0002-8782-6950 M T S Williams *Research Centre for Health, School of Health and Life Sciences, Department of Biological and Biomedical Sciences, Glasgow Caledonian University, Glasgow, UK. mark.williams@gcu.ac.uk.ORCID http://orcid.org/0000-0003-1114-1418 Funding
Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas) RR220088
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Identifiers
PMID42303771
PMCPMC13421325
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390